Danimer Scientific DNMR
DNMR is a post-SPAC bioplastics story whose 'sold-out' demand, $200M take-or-pay contracts, and $1 trillion TAM are misrepresentations — actual utilization is ~28% and Novomer is a Hail Mary.
Thesis
Muddy Waters is short Danimer Scientific, a $1.7bn post-SPAC bioplastics company whose CEO Stephen Croskrey claims 'fully sold-out' 2022 Kentucky capacity backed by $200M+ take-or-pay agreements with PepsiCo, Nestle, and Bacardi. Muddy Waters estimates H1 2021 utilization at ~28% — with persistent finished-goods inventory build and near-zero work-in-process evidencing weak demand. Marquee partnerships are mischaracterized: the PepsiCo bag that won a 2018 bioplastics award is PLA, not PHA, and Mars Wrigley sources say commercial packaging is not expected before 2025. DNMR has revised its capacity plan four times in eight months, and the $152M Novomer acquisition looks like a Hail Mary on a hollowed-out firm whose headcount fell from 60 to 10 and whose technology has never reached commercial scale. The claimed 500-billion-pound / $1 trillion TAM is 'delusional' versus a realistic $4-5bn PHA packaging market, echoing precedents Metabolix and ADM that both abandoned PHA.
SCQA
Danimer Scientific is a $1.7bn post-SPAC bioplastics company producing PHA, with touted marquee partnerships (PepsiCo, Nestle, Bacardi, Mars Wrigley), claims of $200M+ take-or-pay offtake, sold-out 2022 capacity, and a $1 trillion TAM.
DNMR has misled investors: estimated H1 utilization is ~28% not 50%, the award-winning PepsiCo 'PHA' bag is actually PLA, Mars Wrigley is 2025+, capacity plans changed four times in eight months, and Novomer was hollowed out pre-acquisition.
Short DNMR. Muddy Waters concludes the equity story unravels once investors see weak demand, non-binding take-or-pay contracts, ever-shifting capacity claims, and that the $152M Novomer deal is a Hail Mary on unproven technology.
No explicit price target; downside is implied by reframing DNMR from a 'sold-out' scaled producer in a $1 trillion TAM to a sub-commercial demonstration-plant operation in a realistic $4-9bn bioplastics market.
The three reasons
- 1
H1 2021 PHA capacity utilization is ~28%, not the 50% management implies — demand is weak
- 2
Purported $200M take-or-pay deals are non-binding; PepsiCo award-winning 'PHA' bag is actually PLA
- 3
$152M Novomer acquisition is a Hail Mary on a hollowed-out, cash-poor, non-commercial technology
KPIs cited
Pattern membership
Where this document fits across the library's 12 rhetorical / structural patterns.
Precedents cited
- Metabolix PHA business (sold for $10M after ~$300M invested)
- Archer-Daniels-Midland PHA exit
- Saudi Aramco 8-month diligence on Novomer (vs. DNMR's 3 weeks)
- Hindenburg Research ('play the man, not the ball')
Notable slides (6)
Notes
Short report as prose research note, not a slide deck — Times Roman body with footnotes, no original data-viz beyond simple tables. Signature rhetorical move (from p2): 'play the man, not the ball' — attacks management behaviors (shifting capacity plans, Hail Mary M&A, PLA/PHA bait-and-switch) rather than building a DCF. Uses direct CEO quotes ('fully sold-out', '$200M take-or-pay') to set up contradictions. Includes a Chappelle's Show still ('Money is a Helluva Drug') on p12 as rhetorical device. Reproduces three DNMR marketing slides (pp. 10, 13, 17) to attack them directly. Hat tip to Hindenburg in footnote 1. No explicit price target; the 'ask' is the short position itself.